1、WelcomeContentClick below to navigate through the documentGlobal Health innovation milestones in Q3Top 10 questions from shareholdersMSCI upgrades Novartis ESG rating to AAA,its highest ratingUpcoming investor eventMeet Novartis Chief People&Organization Officer,Rob KowalskiFor any questions and com

2、ments,please reach out to:Sloan SimpsonGlobal Head of Investor R+1 862 345 4440Maria Victoria CuevasInvestor Relations Executive Director&ESG H+41 79 586 52 85Edition no.23 Q3 2025 Impact and Sustainability Update to Investors Dear investors and analysts,Our Q3 newsletter starts with an update from

3、the third-party ESG rating agency,MSCI,which has upgraded Novartis to AAA,its highest rating.We also highlight our recent milestones in Global Health innovation,including the Ghana launch of Coartem Baby for the treatment of malaria in newborns and young infants and positive results from our trial i

4、nvestigating Entresto in heart failure caused by Chagas disease.We then feature a Q&A with Rob Kowalski,our Chief People&Organization Officer,discussing what culture means to Novartis.We also invite you to our 12th annual Social Impact&Sustainability investor event.As always,we include top questions

5、 from shareholders during Q3 and our responses.We thank you for your continued engagement.Q3 impact and sustainability update|2ContentClick below to navigate through the documentWelcomeGlobal Health innovation milestones in Q3Top 10 questions from shareholdersMSCI upgrades Novartis ESG rating to AAA

6、,its highest ratingUpcoming investor eventMeet Novartis Chief People&Organization Officer,Rob KowalskiMSCI upgrades Novartis ESG rating to AAA,its highest rating In July,MSCI upgraded Novartis to AAA,its highest ESG rating.Novartis has consistently improved across all MSCI ESG pillars,with the upgra